Deciphering rifampicin resistance among tuberculosis patients who have trace results on Xpert MTB/RIF ultra assay.

INTRODUCTION: The(MTB) detected trace, rifampicin (RIF) resistance indeterminate category of the Xpert MTB/RIF Ultra assay results is usually, non-actionable and requires retesting the samples. We aimed to decipher RIF resistance among tuberculosis patients who have trace and indeterminate results.

METHODS: Four hundred and three (403) MTB detected trace, RIF resistance indeterminate results, which were obtained in Mycobacteriology (BSL-3) and Molecular Diagnostic laboratories, College of Health Sciences, Makerere University from August 2018 to June 2023, having culture results were identified from the laboratory database. Isolates of those that turned out culture positive were retrieved and sub-cultured in liquid media to perform phenotypic first line Drug Susceptibility tests, first line Line-Probe assays (LPA) and repeat GeneXpert ultra.

RESULTS: A total of 31/403 (7.7%) culture positive isolates were identified from the database of which 77.42% (24/31) were positive forcomplex (MTBc). Nineteen (19) out of the identified 24 MTBc were successfully retrieved, cultured and resistance testing performed. Phenotypic Drug susceptibility testing and repeated GeneXpert did not identify any resistance. Only one mutationMUT1 related to isoniazid (INH) resistance was identified using MTBDRplus assay.

CONCLUSION: In this study, we did not identify any missed rifampicin resistance among MTBc culture positive samples that were initially Xpert ultra-trace and rifampicin resistance indeterminate. More studies with bigger sample sizes especially in high MDR-TB settings are required.